BillionToOne Raises $130M in Series D Funding, Expands Prenatal and Oncology Businesses

BillionToOne Raises $130M in Series D Funding

BillionToOne raises $130M in Series D Funding

BillionToOne (Linkedin), a leading biotech research company, recently secured $130M in Series D funding, catapulting their valuation to over $1 billion. With a focus on precision diagnostics for prenatal and oncology applications, BillionToOne is poised to revolutionize the healthcare industry.

Funding Amount: $130 million

Industry: Biotechnology Research

Employee Count: 201-500

CEO: Oguzhan Atay, PhD (CEO Linkedin)

What BillionToOne needs to buy: BillionToOne is seeking partnerships with research institutions, biotech companies, and manufacturers to further develop and enhance their precision diagnostics technology. Additionally, they require marketing and sales support to expand their market reach and raise awareness about their prenatal and oncology products. Companies specializing in precision diagnostics, research, manufacturing, and supply chain solutions are ideal partners for BillionToOne's ambitious growth plans.